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Abstract
A decline in the regenerative capacity of adult stem cells with aging is well documented. As
a result of this decline, the efficacy of autologous stem cell therapies is likely to decline with
increasing donor age. In these cases, strategies to restore the function of aged stem cells
would have clinical utility. Globally, the transcription factor NF-κB is up-regulated in aged tis-
sues. Given the negative role that NF-κB plays in myogenesis, we investigated whether the
age-related decline in the function of muscle-derived stem/progenitor cells (MDSPCs) could
be improved by inhibition of NF-κB. Herein, we demonstrate that pharmacologic or genetic
inhibition of NF-κB activation increases myogenic differentiation and improves resistance to
oxidative stress. Our results suggest that MDSPC “aging” may be reversible, and that phar-
macologic targeting of pathways such as NF-κB may enhance the efficacy of cell-based
therapies.
Introduction
Regenerative medicine and tissue engineering have traditionally focused on stem cell based
approaches for the treatment of disease and injury. At present, clinical trials have taught us
that many obstacles remain to be overcome before cell therapies can become practical thera-
peutic options. One problem is the impact of donor age on stem cell function. There is sub-
stantial evidence that stem cell function declines with age and this contributes to the aging
process [1–5]. Thus, transplantation of older, functionally impaired cell populations results in
a reduced therapeutic efficacy compared to the transplantation of younger cell populations [6–
8]. This is an issue that needs to be addressed given that diseases for which stem cell-based
treatments seem the most promising, such as cardiovascular and neurodegenerative diseases,
are age-related [2, 9]. Considering that the risks associated with immunosuppression may
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outweigh the benefits of allogeneic cell transplants, new strategies aimed at improving aged
stem cell function must be identified.
Molecules that target specific age-related pathways may improve adult stem cell regenera-
tive capacity. Of the many pathways that have been implicated in aging, increased NF-κB
activity has been identified as a major regulator of gene expression programs associated with
aging across diverse tissues [10–12]. For example, increased amounts of NF-κB subunits
have been found in nuclear extracts of aged mouse and rat skin, liver, kidneys, and brain [13].
Genetic inhibition of NF-κB in aged murine skin leads to tissue rejuvenation and changes
in gene expression resembling younger skin [12]. Moreover, systemic inhibition of NF-κB,
either by deletion of one allele of the NF-κB subunit p65 or by chronic administration of an
inhibitor of the kinase upstream of NF-kB, delays aging in Ercc1-/Δ mice, a model of XFE pro-
geroid syndrome [14]. NF-κB activation is also implicated as a barrier to induced pluripotency
in fibroblasts from aged patients, where p65 induces the transcription of Dot1l, a histone H3
methyltransferase that represses pluripotency-related genes [15].
This led us to hypothesize that NF-κB may represent a molecular target for enhancing the
regenerative potential of muscle-derived stem/progenitor cells (MDSPCs). Previous studies
demonstrated that MDSPC-based therapies promote tissue repair following muscle, bone,
cartilage, and cardiac injury [16–19]. However, MDSPC function is impaired with age [4, 20].
For this investigation, we tested whether MDSPCs, isolated from 24 month-old mice, can be
“rejuvenated” by pharmacologic means. We found that treatment with a small molecule inhib-
itor of NF-κB restored the myogenic capacity of aged MDSPCs to the same level as young
MDSPCs, isolated from 14 day-old mice. Similar treatment of senescent bone marrow-derived
mesenchymal stem cells reversed senescence. Furthermore, pretreatment of aged MDSPCs
with an IKKβ/NF-κB inhibitor increased cell survival under oxidative stress. Similarly, we
found that aged p65+/- MDSPCs retained myogenic potential in vitro and had a higher resis-
tance to oxidative stress-induced cell death than aged wild-type (WT) cells. Although NF-κB
inhibition enhanced aged MDSPC differentiation and stress resistance, it did not improve cell
proliferation. Instead, we were able to increase proliferation using three other compounds pre-
viously reported to extend murine lifespan [21, 22]. These results demonstrate that ex vivo
rejuvenation of aged MDSPC function is feasible. Pharmacologic treatment may represent one
strategy for enhancing the efficacy of autologous cell therapies in aging patients.
Materials and methods
Reagents
IKK-2 Inhibitor IV and VII was obtained from EMD Millipore (MA, USA). Aspirin, nordihy-
droguaiaretic acid, and rapamycin were obtained from Sigma-Aldrich (PA, USA).
Cell isolation
Populations of muscle-derived cells were isolated from the leg muscles of 24 month-old (aged)
and 2 week-old (young) WT mice, and 30 month-old p65 haploinsufficient (aged p65+/-)
mice (all F1 C57BL/6:FVB) using the previously described modified pre-plate technique [23].
MDSPCs were collected and expanded in growth medium consisting of 10% FBS, 10% horse
serum, 1% Penn-strep, and 0.5% chick embryo extract (Accurate Chemical Co., New York,
USA) in DMEM. Mesenchymal stem cells (MSCs) were obtained from the bone marrow (BM)
of 23 week-old mice (mature adult) and cultured in high glucose DMEM supplemented with
15% FBS, 2mM glutamine, 100 U/ml penicillin and 0.1 mg/ml streptomycin (all from Sigma-
Aldrich, St Louis, MO, USA). The MSCs were cultured in low oxygen conditions (3% O2) to
avoid oxidative damage. In brief, the BM cells were flushed out from the long bones using a
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syringe following euthanization of the mice. The extracted BM cells were washed by centrifu-
gation and seeded to a concentration of 2.5x105 cells/cm2, while considering this passage 0.
Non-adherent cells were discarded by changing the media 16h later and the culture was further
enriched for MSCs by culturing the BM cells for 3 passages. The generated MSCs displayed a
CD105+, CD106+, CD73+, Sca-1+, CD34-, CD45- and CD31- phenotype, fibroblast-like mor-
phology and multilineage differentiation capacity. All experiments were approved by the Uni-
versity of Pittsburgh or The Scripps Research Institute Institutional Animal Care and Use
Committees.
Myogenic differentiation assay and fast myosin heavy chain (MyHC)
staining
After 15 passages, MDSPCs were plated on 24 well plates (20,000 cells per well) in DMEM sup-
plemented with 2% FBS to stimulate myotube formation. Aged murine MDSPCs were treated
with IKK-2 Inhibitor IV (EMD Millipore) at varying doses during myogenic differentiation to
inhibit NF-κB activation. At the indicated time points, cells were washed, fixed with ice cold
100% methanol, and stained for fast skeletal MyHC. Briefly, cells were blocked with 10% horse
serum for 1 h and then incubated with a mouse anti-MyHC (1:250, Sigma-Aldrich) for 1 h at
room temperature. Cell bound primary antibody was detected with a secondary anti-mouse
antibody conjugated with AlexaFluor594 (1:500, Sigma-Aldrich) by incubation for 30 min.
The nuclei were revealed by DAPI staining. The percentage of differentiated myotubes was
quantified as the number of nuclei in MyHC positive myotubes relative to the total number of
nuclei.
In vitro measurement of cell survival under oxidative stress
MDSPCs were exposed to oxidative stress induced by treatment with 250 uM hydrogen perox-
ide. In order to visualize cell death, propidium iodide (PI), a DNA-binding dye, was added to
culture medium according to the manufacturer’s protocols (BD Bioscience, CA, USA). Using
a previously described live cell imaging system (LCI; Kairos Instruments LLC, Pittsburgh, PA)
[24], 10x bright field and fluorescence images were taken in 10 minute intervals over 24 h [24].
Identifying the number of PI+ cells per field of investigation out of the total cell number deter-
mined the percentage of cell death over time.
Measurement of stem cell senescence
MSC senescence was determined by measurement of senescence specific β-galactosidase activ-
ity (SA β-gal). Cells were seeded at 5,000 cell/cm2 and treated for 48 h with IKK-2 inhibitor
VII (600 nM, EMD Millipore). Then cells were fixed with 2% PFA for 5 min and stained over-
night with X-gal staining buffer, pH 6, containing 2 mg/ml of X-gal (Teknova, Hollister, CA,
USA) at 37˚C. The nuclei were labeled with DAPI (Life technologies, Carlsbad, CA, USA) and
the SA β-gal+ cells were counted manually.
Cell proliferation
Using the LCI system described above, bright field images (10x) were taken at 10 minute inter-
vals over a 72-hour period in three fields of view per well, with three wells per population.
Using ImageJ software (NIH), proliferation was assessed by counting the number of cells per
field of view over 12 hour intervals.
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Statistical analysis
All results are given as the mean ± standard error of the mean. Means were compared using
the student’s T-test or ANOVA with Tukey’s post hoc analysis, as appropriate. Differences
were considered statistically significant when the p-value was <0.05.
Results
Inhibition of NF-κB/IKKβ restores the myogenic potential of aged murine
MDSPCs
We investigated whether NF-κB inhibition would be sufficient to restore the myogenic poten-
tial of aged MDSPCs. Cells were isolated from young (14 day-old) and aged (24 month-old)
mice via the modified preplate technique [23]. Aged and young MDSPCs were cultured under
myogenic conditions with or without the presence of IKK-2 inhibitor IV (IKKi), an inhibitor
of the NF-κB activating kinase, IKKβ, at varying doses. Myogenic differentiation was moni-
tored by bright field microscopy, and after 5 days, treated cells demonstrated an increase in
myotube formation (Fig 1A). We quantified differentiation of myocytes at 5 μM IKKi (the
most effective dose) by immunofluorescent staining for fast skeletal MyHC, a terminal marker
of skeletal muscle differentiation (Fig 1B and 1C). Strikingly, IKKi treatment of aged MDSPCs
increased myogenic differentiation to levels similar to those of young cells. Although all groups
were plated at the same density, after 5 days of culture under myogenic conditions, the total
number of nuclei per field of view was increased in the untreated (vehicle control) aged
MDSPC group (Fig 1D). Interestingly, this was normalized by IKKi treatment. This is in agree-
ment with a previous report that NF-κB activity can inhibit differentiation by delaying exit
from the cell cycle [25]. To check for off-target effects of IKKi, we also assessed the myogenic
Fig 1. NF-κB inhibition improves the differentiation of MDSPCs isolated from old mice. (A) Brightfield images demonstrate a dose dependent
increase in myotube formation following IKKi administration (10x images). (B) Immunofluorescent staining for MyHC demonstrated significantly improved
differentiation following treatment at the 5μM dose (20x magnification), quantified in (C). (D) The total number of nuclei per field of view for experiment in B, C
(*p0.05; ANOVA followed by Tukey post-hoc analysis). (E) IKKi treatment of young WT MDSPCs did not significantly improve differentiation (*p0.05, T-
test).
https://doi.org/10.1371/journal.pone.0179270.g001
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capacity of MDSPCs haploinsufficient for the NF-kB subunit p65 (p65+/-) isolated from 30
month-old mice. Unlike aged WT cells, p65+/- MDSPCs from aged mice did not demonstrate a
significant decline in differentiation compared to young WT cells (p = 0.14, Fig 1C). IKKi
treatment did not enhance differentiation of young WT MDSPCs, indicating this effect was
specific to aged cells (Fig 1E). Taken together, these results demonstrate that IKK/NF-κB inhi-
bition restores the myogenic differentiation potential of aged MDSPCs.
NF-κB inhibition increases MDSPC resistance to hydrogen peroxide
induced oxidative stress
Previous studies from our group demonstrated that MDSPC resistance to oxidative stress,
which declines with donor age, is an important characteristic that distinguishes them from
committed myoblasts and correlates with high regenerative capacity in vivo [4, 26]. As NF-κB
is known to be a stress response pathway [27, 28], we examined the effect of IKK/NF-κB inhi-
bition on cell survival in resppnse to hydrogen-peroxide (H2O2) induced oxidative stress.
Briefly, cells were exposed to H2O2 in proliferation medium containing PI, a fluorescent DNA
stain. Cell survival was measured by using live cell imaging (LCI) for up to 24 h. Pretreatment
of the cells with IKKi significantly increased survival of MDSPCs isolated from aged mice.
Likewise, genetic depletion of p65 improved MDSPC oxidative stress resistance (Fig 2).
Drugs that extend the lifespan of mice promote proliferation of MDSPCs
Although IKK/NF-κB inhibition improved myogenic differentiation and stress resistance, it
had the opposite effect on cell proliferation. However, we cannot exclude the possibility that
Fig 2. NF-κB inhibition improves the oxidative stress resistance of MDSPCs isolated from old mice.
MDSPCs were exposed to 250 μM H2O2 and monitored by live cell imaging for up to 24 hours. IKKi treated
aged WT MDSPCs and aged p65+/- MDSPCs demonstrated improved survival compared to vehicle treated
aged WT MDSPCs (*p0.05 Aged WT vs +IKKi; +p0.05 Aged WT vs Aged p65+/-; ANOVA followed by
Tukey post-hoc analysis).
https://doi.org/10.1371/journal.pone.0179270.g002
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the enhanced myogenic differentiation did not indirectly contribute to the effect of IKK/NF-
κB inhibition on cell proliferation, as cell cycle withdrawl preceeds terminal differentiation
[29]. Interestingly, we found that after 48 h of IKK/NF-κB inhibition, senescence of bone mar-
row-derived mesenchymal stem cells (BM-MSCs) was reduced, as assessed by beta-galactosi-
dase positivity, a commonly used marker of senesence [30, 31] (Fig 3). This suggests that NF-
κB may play a role in stem cell self-renewal and senescence in at least BM-MSCs. To determine
if other lifespan extending interventions, in addition to inhibiting NF-κB activation [14],
improve adult stem cell function, we tested the effect of several hits from the National Institute
on Aging (NIA) Intervention Testing Program (ITP) [32] for their ability to increase MDSPC
self-renewal. We tested a number of compounds reported to extend lifespan in mice, including
aspirin, the antioxidant nordihydroguaiaretic acid (NDGA) [21], and the mTOR inhibitor
rapamycin [22]. All three significantly increased proliferation (self-renewal) of MDSPCs iso-
lated from aged mice (Fig 4A). We also measured the effect of these compounds on aged
MDSPC myogenic differentiation. In contrast to NF-kB inhibition, which did not promote
proliferation but did increase differentiation, aspirin, NDGA, and rapamycin all decreased dif-
ferentiation (Fig 4B). Considering that proliferation and differentiation are mutually exclusive,
this result is not surprising. Based on these data, different pharmacologic agents likely need to
be used to first expand and then differentiate stem cells isolated from aged individuals.
Discussion
A decline in the function of tissue-resident stem cells is likely to contribute to the decreased
wound healing and tissue regeneration that comes with age [1]. For example, skeletal muscle
injury that would lead to the regeneration of functional tissue in children, instead leads to pro-
longed inflammation and fibrosis in older adults [33]. In skeletal muscle, this phenomenon is
partially related to the functional decline of satellite cells, the skeletal muscle stem cell. In land-
mark experiments, the dysfunction of murine satellite cells isolated from aged mice was res-
cued by exposure to young mouse serum [34, 35]. This suggests that age-associated stem cell
decline is reversible and may be due to signals from the aged tissue environment (niche).
Fig 3. NF-κB inhibition decreases senescence in BM-MSCs. BM-MSCs were treated for 48 hours with IKK
inhibitor VII and then stained for senescence-associated beta-galactosidase (SA β-gal) expression, which
demonstrated a decrease in cell senescence (*p0.05, T-test).
https://doi.org/10.1371/journal.pone.0179270.g003
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Thus, ex vivo priming to “rejuvenate” cells may be a viable approach for enhancing the func-
tion of cell-based therapies in the elderly [1].
Here we tested whether the phenotype of murine MDSPCs isolated from aged organisms
could be improved by pharmacologic means. We previously described the anti-myogenic role
of NF-κB in MDSPC differentiation [36], and the mechanisms through which NF-κB blocks
myoblast differentiation have been thoroughly investigated [25, 37]. Furthermore, a recent
report indicates that NF-κB activation in aged skeletal muscle fibers reduces satellite cell myo-
genic differentiation potential [38]. Indeed, we identified the NF-κB pathway as a potent target
to restore the myogenic differentiation potential of aged MDSPCs. We also found that resis-
tance to oxidative stress, an important stem cell characteristic [39], was also elevated in both
p65 deficient and IKKi-treated aged cells. This is in line with a previous report in which we
found that donor p65+/- MDSPCs have enhanced survival in vivo following transplantation to
injured host skeletal muscle [40]. Furthermore, in a mouse model of accelerated aging, block-
ade of NF-κB reduced oxidative stress-induced DNA damage [14]. Based on our data, NF-κB
activation in aged cells in response to oxidative stress might predominantly act in a pro-death
or pro-cell senescence manner. Although NF-κB is traditionally considered a survival factor,
under some circumstances, such as DNA damage-triggered apoptosis, a pro-apoptotic role for
NF-κB has been well documented [41–43]. Further investigation will be necessary to deter-
mine if this is the case during oxidative stress-induced MDSPC death.
Although targeting NF-κB did not improve MDSPC proliferation, we identified three other
compounds, NDGA, rapamycin, and aspirin that promote MDSPC self-renewal ex vivo. In
large, multicenter studies, all three of these compounds extend the lifespan of male mice [21,
22]. In support of our findings, rapamycin prevents senescence of aged hematopoietic stem
cells during ex vivo expansion [44], reduces MDSPC senescence, and improves myogenic
differentiation of progeroid MDSPCs [45]. Interestingly, aspirin has been reported to pro-
mote endothelial progenitor cell migration and delay senescence, while having no effect on
proliferation [46]. The effects of NDGA on stem cells are less understood. Future studies will
Fig 4. Multiple compounds improve aged MDSPC proliferation (self-renewal). (A) Aged MDSPCs were cultured in medium containing aspirin,
nordihydroguaiaretic acid (NDGA), or rapamycin, and proliferation was monitored by live cell imaging for up to 60 hours, or (B) cells were treated in fusion
medium and assessed for myogenic differentiation after 5 days (*p0.05 Aged WT vs Treated; ANOVA followed by Tukey post-hoc analysis).
https://doi.org/10.1371/journal.pone.0179270.g004
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be required to determine the exact mechanisms through which these compounds exert their
effects on MDSPCs and whether treatment ex vivo will improve stem cell function in vivo.
Nonetheless, our data indicate that pharmacologic strategies can improve stem cell function in
vitro, and such an approach may prove useful to enhance cell therapies aimed at an aging
patient population.
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